Fort Washington Investment Advisors Inc. OH Purchases 18,876 Shares of Bristol-Myers Squibb (NYSE:BMY)

Fort Washington Investment Advisors Inc. OH grew its position in Bristol-Myers Squibb (NYSE:BMY - Free Report) by 0.7% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The firm owned 2,592,397 shares of the biopharmaceutical company's stock after purchasing an additional 18,876 shares during the period. Bristol-Myers Squibb comprises about 1.0% of Fort Washington Investment Advisors Inc. OH's portfolio, making the stock its 27th largest position. Fort Washington Investment Advisors Inc. OH owned approximately 0.13% of Bristol-Myers Squibb worth $158,110,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Pinney & Scofield Inc. bought a new position in Bristol-Myers Squibb in the fourth quarter valued at $25,000. Park Square Financial Group LLC bought a new position in Bristol-Myers Squibb in the fourth quarter valued at $26,000. Fairway Wealth LLC bought a new position in Bristol-Myers Squibb in the fourth quarter valued at $28,000. Transce3nd LLC bought a new position in Bristol-Myers Squibb in the fourth quarter valued at $28,000. Finally, Global Wealth Strategies & Associates grew its position in Bristol-Myers Squibb by 137.5% in the first quarter. Global Wealth Strategies & Associates now owns 475 shares of the biopharmaceutical company's stock valued at $29,000 after purchasing an additional 275 shares in the last quarter. 76.41% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

BMY has been the subject of a number of analyst reports. Argus raised shares of Bristol-Myers Squibb to a "hold" rating in a research report on Friday, April 25th. Cantor Fitzgerald reissued a "neutral" rating and issued a $55.00 price objective on shares of Bristol-Myers Squibb in a research report on Tuesday, April 22nd. Wall Street Zen downgraded shares of Bristol-Myers Squibb from a "strong-buy" rating to a "buy" rating in a research report on Friday, June 6th. William Blair reissued a "market perform" rating on shares of Bristol-Myers Squibb in a research report on Friday, April 25th. Finally, Piper Sandler initiated coverage on shares of Bristol-Myers Squibb in a research report on Tuesday, April 22nd. They issued an "overweight" rating and a $65.00 price objective for the company. Two investment analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of "Hold" and a consensus target price of $58.00.

Bristol-Myers Squibb Price Performance

Shares of Bristol-Myers Squibb stock traded up $0.52 during midday trading on Thursday, hitting $50.68. 9,595,506 shares of the company traded hands, compared to its average volume of 13,030,732. The stock has a market cap of $103.14 billion, a price-to-earnings ratio of -11.47, a PEG ratio of 2.07 and a beta of 0.38. The company has a debt-to-equity ratio of 2.90, a quick ratio of 1.15 and a current ratio of 1.25. The firm's fifty day moving average price is $48.87 and its 200-day moving average price is $54.88. Bristol-Myers Squibb has a 12 month low of $39.35 and a 12 month high of $63.33.

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last posted its quarterly earnings data on Thursday, April 24th. The biopharmaceutical company reported $1.80 EPS for the quarter, beating analysts' consensus estimates of $1.50 by $0.30. Bristol-Myers Squibb had a negative net margin of 18.53% and a positive return on equity of 13.93%. The company had revenue of $11.20 billion for the quarter, compared to analyst estimates of $10.77 billion. During the same period in the prior year, the firm posted ($4.40) EPS. The company's quarterly revenue was down 5.6% on a year-over-year basis. As a group, sell-side analysts forecast that Bristol-Myers Squibb will post 6.74 earnings per share for the current year.

Insiders Place Their Bets

In related news, EVP Samit Hirawat bought 4,250 shares of the company's stock in a transaction on Friday, April 25th. The stock was acquired at an average cost of $47.58 per share, for a total transaction of $202,215.00. Following the completion of the transaction, the executive vice president now directly owns 83,513 shares in the company, valued at $3,973,548.54. This trade represents a 5.36% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Insiders own 0.09% of the company's stock.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.